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Abstract
Equine herpesvirus-1 (EHV-1) infection remains a significant problem despite the widespread use of vaccines. The
inability to generate a protective immune response to EHV-1 vaccination or infection is thought to be due to
immunomodulatory properties of the virus, and the ORF1 and ORF2 gene products have been hypothesized as
potential candidates with immunoregulatory properties. A pony infection study was performed to define immune
responses to EHV-1, and to determine if an EHV-1 ORF1/2 deletion mutant (ΔORF1/2) would have different disease
and immunoregulatory effects compared to wild type EHV-1 (WT). Infection with either virus led to cytokine
responses that coincided with the course of clinical disease, particularly the biphasic pyrexia, which correlates with
respiratory disease and viremia, respectively. Similarly, both viruses caused suppression of proliferative T-cell
responses on day 7 post infection (pi). The ΔORF1/ORF2 virus caused significantly shorter primary pyrexia and
significantly reduced nasal shedding, and an attenuated decrease in PBMC IL-8 as well as increased Tbet responses
compared to WT-infected ponies. In conclusion, our findings are (i) that infection of ponies with EHV-1 leads to
modulation of immune responses, which are correlated with disease pathogenesis, and (ii) that the ORF1/2 genes
are of importance for disease outcome and modulation of cytokine responses.
Introduction
Equine herpesvirus-1 remains one of the most common
viral infections of horses causing respiratory disease, epi-
demic abortion, and outbreaks of equine herpes mye-
loencephalopathy (EHM) [1]. Primary infections with
EHV-1 lead to establishment of latent infection within
the first weeks or months of life. The two main strate-
gies for controlling EHV-1 infection and disease are
management practices and vaccination, however immu-
nity established after either infection or vaccination is
short lived and incomplete [1].
Equine adaptive immune responses and protection
from EHV-1 have been extensively studied. While virus-
neutralizing (VN) antibodies play a role in reduction of
nasal viral shedding [2], cytotoxic T-lymphocytes (CTLs)
are most critical for protection from clinical disease,
viremia and nasal viral shedding [2-4]. In contrast, innate
immunity to EHV-1 infection is poorly characterized.
Innate immunity in mice and humans has been demon-
strated to be critcally important for immediate protection
as well as for shaping subsequent adaptive immune
responses via initial interaction of viral pathogens with
pattern recognition receptors (PRR) that prime and direct
subsequent immunological events [5]. Characterization of
early and innate responses to EHV-1 may help explain
the hosts failure to generate long-lasting immunity.
Viruses have developed an array of strategies to cir-
cumvent host immunity, and for EHV-1 it is thought that
the lack of long-lasting immunity is due to immunomo-
dulatory properties of the virus [6-11]. Strategies
employed by EHV-1 include interference and modulation
of NK-cell lysis, alteration of cytokine network responses
that ultimately affect B- and T-cell responses, loss of effi-
cient antigen presentation and chemoattraction of profes-
sional antigen presenting cells, antibody dependent
cytotoxicity, and CTL responses [12].
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Most research on EHV-1 immunomodulation has
been performed in vitro or using mouse models. Few in
vivo equine studies have been performed [8,13,14] and
these have focused on clinical outcomes and viremia
while innate and early immune responses were not
examined in detail. All EHV-1 genes are expressed
within the first hours of infection, and may therefore
target early innate immune responses long before the
onset of an adaptive immune response.
Amongst current EHV-1 vaccines in use, modified live
vaccines (MLV) typically perform best [15]. Studies have
shown clinical and virological protection from EHV-1
infection after MLV vaccination with attenuated EHV-1
strains (RacH, NY03-H3) containing deletions in the IR6
gene and the left terminus of the genome (ORF1/2
genes) [16-18] (Figure 1a). The IR6 gene has already
been intensively studied in vitro as well as in vivo
[19-21], but no information is available to date regarding
the functions of the ORF1/2 genes. Based on the fact
that the genes ORF1 and 2 are (i) expressed very early
in infection and (ii) absent in the attenuated RacH
strain, we choose to study their possible immunoregula-
tory role in an equine model. For this purpose, a recom-
binant Ab4 mutant was generated where the ORF1 and
ORF2 genes were deleted (Ab4ΔORF1/2) (Figure 1a).
Ponies were infected with Ab4 wild type (WT) or
ΔORF1/2 virus and the effects on innate and adaptive
immune responses, and on severity of clinical disease,
nasal viral shedding and viremia was determined.
Material and methods
Experimental animals
Nineteen yearling ponies of both sexes were used for
this study. All ponies were tested for prior exposure to
EHV-1 using virus neutralization tests and none of the
ponies exhibited titers > 128. Ponies were fed twice a
day with a diet of hay and pelleted concentrate. The
maintenance and experimental protocols followed the
animal care guidelines of the Animal Care and Use
Committee, Colorado State University.
Equine herpesvirus virus preparation, isolation and
kinetics
This experiment used the neuropathogenic EHV-1 strain
Ab4, a native equine strain that is known to cause
respiratory disease, abortions and neurological disease. In
addition, an Ab4 mutant virus lacking the ORF1 and
ORF2 genes (Ab4ΔORF1/2) was generated as follows.
A recombinant BAC, pAb4ΔORF1/2 was generated by
two-step Red-mediated (en passent) recombination [19]
using the mutagenesis primers ORF1/2_FW: 5’CGAGGG
AGTTTCGCGGGGCCGCGCCTCCTCTGTCTCCATCG
GTAGGGTTTGAGACGTGTAAGGATGACGCGATAA
GTAGGG3’ and ORF1/2_RV:5’TCCAGCGTGGAG
GAGGCGCATACACGTCTCAAACCCTACCGATG
GAGACA GAGGAGGCGCCAACCAATTAACC AA-
TTCTGATTAG 3’(underlined sequence indicates the
template binding region of the primers for PCR amplifica-
tion with pEPKanS). Parental and mutant BAC DNA was
isolated, digested with NotI and analyzed by 0.8% agarose
gel electrophoresis after visualization of DNA fragments
with ethidium bromide (EtBr) (Figure 1b). In addition, the
identity of the mutant BAC DNA’s was also confirmed by
sequencing, using the primers ORF1/2-F (5’ CCCTCT
ACGGTTTTCTTCGAGGCCG 3’) and ORF1/2-R
(5’ CCTAGGCGATG TGTGCAGCCGAGGC 3’) (data
not shown). Virus was reconstituted after co-transfection
of 5 μg of BAC DNA into rabbit kidney (RK13) cells with
2 μg of plasmid DNA expressing the full-length gp2, using
the CaPO4 precipitation method as previously described
[22,23]. At day 5 after co-transfection, supernatants were
harvested and transferred to fresh plates of RK13 cells,
and recombinant non fluorescing virus plaques were
picked and purified to homogeneity by two rounds of pla-
que purification [22]. To detect gp2 expression, the mono-
clonal antibody (MAb) 3B12 was used and western
blotting was performed exactly as described previously
[23,24] (Figure 1c). Before in vivo inoculation of ponies
with these strains, the growth kinetics of Ab4 WT and
Ab4 ΔORF1/2 were compared in RK13 cells and equine
dermal cells (NBL6) grown in minimal essential medium
(Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin and
0.1 mg/mL streptomycin (Sigma-Aldrich) in three inde-
pendent experiments. For this purpose, 1 × 105 RK13 or
NBL-6 cells were infected at a multiplicity of infection
(MOI) of 3. Virus was allowed to attach to the cells for 30
min at 4°C, followed by a 1.5 h penetration period at 37°C,
and then all excess virus was washed off. At different time
points post infection (pi), cells and supernatants were
collected and intra- and extracellular viral titers were
determined by plating onto RK13 cells.
Experimental design and infection
Nineteen ponies were randomly assigned to 3 groups.
Group 1 (n = 7) were infected with Ab4 WT virus (Ab4
WT group), group 2 (n = 7) were infected with Ab4
ΔORF1/2 (Ab4 ΔORF1/2 group) and group 3 (n = 5)
were uninfected ponies (Controls). The infection groups
were infected by intranasal instillation of 1 × 107 PFU of
the respective viruses in 7mLs of saline. During the
study ponies were housed in geographically separate
groups, and kept separate from all other horses. Infec-
tions and sample collections were performed by separate
teams so as to avoid cross contamination of the different
experimental groups.
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Figure 1 (A). Genomic organization of RacH, Ab4 wild type and the recombinant Ab4 OFR1/2 deletion mutant. Shown is the RacH and
Ab4genome with a detailed organization of parts of the unique long (UL) and unique short (US) regions, along with parts of the inverted and
terminal repeat regions (IR & TR, shaded in grey). In addition, the genome of the recombinant Ab4 ORF1/2 mutant is shown where the genes
ORF1 and ORF2 were deleted. B. Restriction fragment length polymorphisms (RFLPs) that confirm correct deletion of the ORF1 and 2 genes in
the pAb4 background. BAC DNA was digested with NotI and separated by electrophoresis on a 0.8% agarose gel. Staining of the gel with
ethidium bromide (EtBr) shows changes in RFLP patters obtained, indicated by circles, after the first recombination (insertion of the aphA1 gene;
pAb4 intermediate) and the second recombination (removal of aphA1 gene and the ORF1/2 genes; pAb4ΔORF1/2). (C). Western blot analysis
detecting the expression of gp2 in cellysates of cells infected with reconstituted or not reconstituted Ab4ΔORF1/2. Mock-infected cells (RK13
cells) were included as controls. Cellysates were loaded and separated by SDS-12% PAGE under reducing conditions. Separated proteins were
transferred to a nitrocellulose membrane and incubated with monoclonal antibodies (mAb) 3B12 (against gp2; 1:10) or the control mAb L3ab
(against ETIF, 1:2000). The sizes of the PageRuler Prestained protein Ladder (Fermentas) are given in thousands.
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Clinical data
Physical examinations were conducted prior to infection
and daily for thirteen days and every other day from day
14 to day 21 pi. For each day, a total clinical score was
calculated by checking for the presence of five clinical
signs (cough, fever defined as a rectal temperature >
38.6°C, ocular discharge, nasal discharge and depression)
as described previously [25]. Each of these clinical signs
received a score of 1 if present and 0 if absent in order
to calculate the total clinical score per animal.
Sample collection
Experimental samples were taken as indicated in Table 1.
Nasal swab samples for virus isolation were collected
using Dacron swabs (Baxter Healthcare Corporation,
McGaw Park, IL, USA) and were stored in 1 mL of virus
transport medium (PBS containing 5% glycerol, 800 U
m/L Penicillin/Streptomycin, 200 U m/L Gentamycin,
and 100 U m/L Nystatin) at -70°C. Blood for detection of
cell-associated viremia was collected by jugular venipunc-
ture into heparinized tubes. Blood for detection of neu-
tralizing antibodies was collected by jugular venipuncture
into serum separator tubes (BD, Franklin Lake, NJ, USA)
and serum samples were aliquoted and stored at -20°C
until analysis. Blood for cytokine measurement was col-
lected by jugular venipuncture using the PAXgene™
RNA system (BD) and RNA was isolated and processed
according to manufacturer’s instructions. Nasal secre-
tions for cytokine measurement were collected using
tampons in the ventral nasal meatus for a minimum of
20 min as previously described [3], and stored at -20°C
until analysis. For lymphoproliferative responses and
cytokine production following re-stimulation, blood was
collected into heparin as described previously [25].
Nasal virus shedding
Viral DNA in nasal swab samples was isolated using the
Qiamp DNA blood minikit, according to manufacturer’s
instructions (Qiagen, Inc., Valencia, CA, USA). To
determine nasal virus shedding, viral DNA load was
determined by real time PCR using a specific probe
recognizing glycoprotein B (gB) of EHV-1, as previously
described [26]. To ensure no cross-contamination had
occurred between the different experimental groups,
nasal swab DNA on day 2 pi from all experimental ani-
mals was tested for presence of Ab4 WT or Ab4
ΔORF1/2 using the following primer set, based on the
published Ab4 sequence (Acc # N_001491): FP: 5’- CAA-
CAACCCTGGGCTCTTTA -3’(5’ at position 80 flanking
the ORF1gene) and RP: 5’- GATTCGCACCTCATCTC-
CAC -3’(5’ at position 2132 flanking the ORF 2 gene), at
standard cycling conditions. Using these primers, the
expected product for ponies infected with Ab4 WT
would be 1.25 kb and around 0.4 kb for ponies infected
with Ab4 ΔORF1/2. The PCR results confirmed that no
cross-contamination with the different viruses between
the pony groups had occurred (data not shown).
Cell-associated viremia
For detection of cell-associated viremia, peripheral blood
mononuclear cells (PBMCs) were isolated from hepari-
nized blood using density gradient centrifugation over
Histopaque-1077 (Sigma, St. Louis, MO, USA). Viral
and cellular DNA was isolated using the Qiamp DNA
blood minikit according to manufacturer’s instructions
(Qiagen, Inc.). Viral load was determined by real time
PCR, as described for determining viral load in nasal
swabs in the above section. Beta actin was used as the
cellular housekeeping gene using primer and probe
sequences developed previously [27]. Viral load was
expressed as the log of EHV-1 gB DNA copies/106
b-actin copies.
Antibody responses to EHV-1
Virus neutralizing antibody titers in serum sample were
determined as described previously [28]. Antibody
responses were also independently evaluated using a
kinetic enzyme-linked immune absorbent assay (ELISA)
as described previously [18]. This kinetic ELISA was used
because it typically allows for more accurate differentia-
tion between the IgG isotype responses when compared
to a conventional endpoint ELISA due to decreased
Table 1 Experimental design
Day of study* - 2 0 1 2 3 4 5 6 7 9 14 21 56 78 96
Physical Exam X X X X X X X X X X X X ad X
Shedding &Virema X X X X X X X X X X X X ad X
SN titers X X X X X X X
Nasal cytokines X X X X
Paxgene mRNA X X X X X X X X
Re-call responses:
-Prolif. X X X X X X X
-Cytokines X X X
*Day 0: day of infection; +ad indicates sampling on alternating days.
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variability and measurement as a continuous titer. Briefly,
microtiter plates (MaxiSorb, Nalge Nunc Int., Rochester,
NY, USA) were coated with EHV-1 virus antigen in a
final concentration of 5 μg/mL. After washing, serum
samples and EHV-1 positive and negative control sera
were diluted 1:200 in phosphate buffer and incubated on
plates followed by washing and addition of cell culture
supernatants of monoclonal antibodies (Mab) recogniz-
ing each of the equine IgG sub-isotypes (IgGa, IgGb,
IgGc and IgG(T)). A peroxidase conjugated goat anti-
mouse IgG(H + L) antibody (Jackson ImmunoResearch,
West Grove, PA, USA) was added before washing and
addition of substrate solution. Kinetic plate reads were
obtained at 45, 90 and 135 seconds after substrate addi-
tion in an ELISA reader (ELx808, Biotek Instruments
Inc., Winooski, VT, USA) at 630 nm and the generated
slope value for each sample was multiplied by 1 000 for
data presentation.
Measurement of cytokine mRNA expression in blood
Total RNA from PAXgene™ tubes was extracted
according to manufacturers instructions and 1 μg of
RNA was reverse-transcribed. Cytokine/chemokine spe-
cific cDNA was quantified by real-time PCR using
equine-specific, intron-spanning primers for IL-1, IL-2,
IL-8, IL-10, IL-12, IFN-g, TNF-a, TGF-b, FoxP3, Tbet,
GATA3 and the housekeeping gene b-gus with an
Applied Biosystems 7900 sequence detection system.
For primer and probe sequences see [29]. Relative quan-
tity (RQ) of each gene was determined with the 2(-Delta
Delta C(T)) method [30] using the average day -2 values
of all horses for each gene as calibrators.
Measurement of IL-4, IL-10, IFN-a in nasal secretions
Nasal secretions were tested for the presence of IL-4, IL-
10 and IFN-a with a fluorescent bead-based system
(Luminex IS 100 instrument, Luminex Corp. Austin, TX,
USA) [31] as previously described [32]. The data were
reported as median fluorescent intensities. For standard
curve fitting and subsequent calculation of concentra-
tions in samples the logistic 5p formula (y = a + b/(1 +
(x/c)^d)^f) was used (Luminex 100 Integrated System
2.3).
Non-specific and EHV-1-specific lymphoproliferative
responses
For measurement of lymphoproliferative responses in
lymphocyte subsets, 5-6-Carboxyfluorescein diacetate
succinimidyl ester (CFSE) was used to stain and detect
cell division using the CyAn™ ADP - Multiparameter
Flow Cytometer (Dako Corporation, Fort Collins, CO,
USA). Isolated PBMCs were re-suspended at 1 × 107 in
1 mL of PBS before adding CFSE at a concentration of
5 μM. After 8 min incubation at room temperature, the
reaction was quenched using 2 mL FCS and washed
twice. Cells were re-suspended in media (RPMI 1640
containing 2 mM L-glutamine, streptomycin 10 mg/mL,
penicillin 10 000 units/mL, 2 mM sodium pyruvate,
2 mM b-mercaptoethanol, 10 mM HEPES and10% FCS;
Gibco/Invitrogen, Carlsbad, CA, USA). Stained and
unstained cells were plated in 24 well tissue culture
plates (Corning Inc., NY, USA) at 2 × 106 cells/well
before adding media, heat-inactivated Ab4 at an MOI of
5, or PHA at 0.2 or 1 μg/mL (Sigma, St. Louis, MO,
USA) incubation in a humidified 37°C incubator with
5% CO2. Following a 5-day incubation period, cells were
harvested by centrifugation at 300 g and re-suspended
in FACS buffer (PBS with 0.4% FCS, and 0.1% NaNH3)
before plating and staining aliquots with cell superna-
tants of the following anti-equine monoclonal antibo-
dies: CVS19 (anti-equine CD13 control Ab), CVS4
(anti-equine CD4), CV8 (anti-equine CD8) [33]. After
washing, cells were stained with Goat anti-mouse IgG-1
Tricolor conjugate (Caltag Laboratories, Burlingame,
CA, USA) for detection. B cells were stained using a
directly conjugated goat a-equine IgG light chain anti-
body (Jackson ImmunoResearch, West Grove, PA, USA)
at a 1:10 dilution. Lymphoproliferative responses for
each cell subset were analyzed using flow cytometry and
calculated by subtracting the percent of proliferating
cells stimulated with media alone from the percent of
proliferating cells stimulated with either EHV-1 or PHA.
Cytokine mRNA responses to in vitro re-stimulation
with EHV-1
IFN-g, Granzyme B, and Perforin mRNA responses to
re-stimulation with EHV-1 was examined by real time
PCR as described above. For re-stimulation experiments,
PBMCs collected at days 56, 74 and 96 pi were plated at
a concentration of 4 × 106 cells in 1.2 mL of media per
well, and re-stimulated with either heat-inactivated
EHV-1/Ab4 at a MOI of 5 or incubated with media
alone or 1 μg mL of PHA (Sigma) in a humidified 37°C,
5% CO2 incubator for 48 h. Cells were collected by pel-
leting at 300 g for 3 min. Total RNA was recovered
using TRIzol and the RNeasy Mini Kit protocol plus
DNAse treatment (Quiagen, Inc.) and reverse tran-
scribed. IFN-g, Granzyme B, and Perforin cDNA was
measured by real time PCR assay using specific probes
and primers as described above.
Statistical analysis
All continuous data were evaluated for assumptions of
normality prior to performing a linear regression analy-
sis. The overall effect of both virus groups on the out-
come, when compared to uninfected control group, was
determined using a multivariable linear regression analy-
sis. The difference between the experimental groups on
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each day pi was evaluated using a bivariable linear
regression analysis stratified by “day”. A separate analy-
sis to compare post-infection days to the pre-infection
day was performed within each virus group. The data
on temperature and viremia was dichotomized to evalu-
ate the probability of occurrence of fever or viremia in
the two infection groups when compared to the con-
trols, using a multivariable logistic regression analysis
taking into account the repeated measurements on
ponies across different days. A bivariable logistic regres-
sion analysis was performed to evaluate the probability
of occurrence of fever on febrile days and viremia on
viremic days in the Ab4 ΔORF1/2-infected group com-
pared to the WT-infected group. When multiple com-
parisons occurred within one analysis, a Bonferroni
adjustment of p-value was used to evaluate statistical
significance. A p-value of < 0.05 was used to determine
statistical significance.
Results
Growth kinetics of Ab4 WT and Ab4 ΔORF1/2
Growth kinetics of Ab4 WT and Ab4 ΔORF1/2 were
evaluated in RK13, (Additional file 1: Figure S1) and
NBL6 cells (not shown). Measurement of both intracel-
lular and extracellular virus titers showed that deletion
of the ORF1/ORF2 genes did not alter in vitro growth
kinetics when compared to Ab4 WT.
Clinical signs following EHV-1 infection
Animals in both infection groups showed signs of EHV-1
respiratory disease including pyrexia, lethargy, ocular and
nasal discharge, and coughing between day 1 and day 14
pi, while none of the uninfected control animals showed
any sign of clinical disease (Figure 2a). Differences in clini-
cal scores were not significantly different between Ab4
WT- and Ab4 ΔORF1/2-infected ponies. Body tempera-
tures are shown in Figure 2b and temperatures of both
Figure 2 Mean clinical score, body temperature, viral nasal shedding, and viremia following infection. Clinical scores (a). Body
temperatures are indicated in degree Celcius and the dotted line indicates fever (defined as a T ≥ 38.6°C) (b). Viral nasal shedding is represented
as mean log gB copy numbers in nasal swabs as determined by real time PCR (c) and viremia is represented as log gB copy numbers/106
copies of b-actin in PBMCs (d). Controls (n = 5): white circles, Ab4 WT infected (n = 7): grey triangles, Ab4 delta ORF1/2 infected (n = 7): black
squares. Data are displayed as means + SEM.
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infection groups were significantly higher then in unin-
fected controls (p < 0.0001). The duration of the primary
fever was significantly shorter in Ab4 ΔORF1/2-infected
ponies compared to Ab4 WT-infected ponies (p < 0.0001).
Nasal virus shedding and cell-associated viremia
Nasal virus isolation and viremia results are shown in
Figure 1c and 1d respectively. As observed for clinical
data, only animals in infection groups exhibited nasal
viral shedding and viremia, while no viral DNA was
detected from uninfected controls throughout the experi-
ment. Infection with Ab4 ΔORF1/2 resulted in reduced
nasal virus shedding when compared to Ab4 WT, both in
terms of duration and magnitude of virus shedding
(Figure 2c), and these differences were statistically signifi-
cant from days 1 through 5 post-infection, (p = 0.0005).
Viremia results are shown in Figure 2d; both infection
groups were viremic over multiple days, while control
animals were not viremic (p < 0.001). Viremia was not
significantly different between the infected groups.
Antibody responses
Serum neutralization (SN) titers and antibody isotype
responses are shown in Figure 3. SN titer responses are
displayed after log transformation, because SN titers
were not normally distributed. No increases in antibody
responses occurred prior to infection. Following infec-
tion, SN titers, IgGa, IgGb and IgGc antibodies in both
infection groups increased significantly when compared
to the controls (p-values: SN titers < 0.001, IgGa < 0.04,
IgGb < 0.04, IgGc < 0.04). SN titers started to rise by
day 6 pi in both infection groups, peaked by day 21 and
slowly declined but were still well above pre-infection
levels on day 74 pi (Figure 3a). SN titers were not signif-
icantly different between the infection groups. IgGa anti-
body responses to EHV-1 were apparent following
infection with both viruses. Responses in the Ab4
ΔORF1/2-infected group were significantly higher on
days 14 and 21 pi as compared to the Ab4 WT-infected
group (p = 0.01 and 0.03 respectively, Figure 3b). Over-
all, the pattern of IgGa responses were of a shorter
duration compared to SN responses. In contrast, the
IgGb responses paralleled the pattern of SN responses
in both infection groups, and no significant differences
between infection groups were observed (Figure 3c).
The IgG(T) responses differed from all other antibody
response patterns and were of very low amplitude
(Figure 3d). Pre-existing anti-EHV-1 IgG(T) antibody
responses were detectable in all groups and increased
upon infection, but increases in anti-EHV-1 IgG(T)
levels were only statistically significant in the Ab4
ΔORF1/2-infected group (day 14 pi p = 0.007, day 21 pi
p < 0.0001). The IgGc responses were of low amplitude,
and did not differ between infection groups (Figure 3e).
Cytokine expression in blood and nasal secretions
Figure 4 shows the relative quantity (RQ) values of cyto-
kine expression levels in blood samples at days 1-7 pi.
The major findings were that (i) Infection with both
viruses resulted in increased cytokine responses on days
1 and/or 2 pi (IL-1, TNF-a, and TGF-b in Ab4 WT-
infection group; IL-1, TNF-a, IL-12, Tbet, and TGF-b
in Ab4 delta ORF1/2 infection group) and days 6 and/or
7 pi, (INF-g, and TGF-b in both infection groups, IL-10
significant in the Ab4 delta ORF1/2 infection group
only) coinciding with the biphasic temperature response
and onset of respiratory disease and viremia, while cyto-
kine mRNA expression (IL-1, IL-2, IL-8) was decreased
in the Ab4 WT infection group when compared to
uninfected controls on days 3, 4, and 5 pi, (ii) Tbet
mRNA expression in PBMCs of the Ab4 delta ORF1/2
infection group was significantly higher than that seen
in either the control group or the AB4 WT-infection
group on days 1 and 2 pi (p < 0.001). In addition, the
decrease in IL-8 mRNA levels seen in the Ab4 WT
infection group was attenuated in the Ab4 ΔORF1/2
infection group, and Tbet levels in the Ab4 ΔORF1/2
infection group were higher compared to both the Ab4
WT infection group and the controls during this period
although not quite reaching significance (p-values: 0.08
on day 3 and 0.07 on day 5).
In nasal secretions, IL-4 was not detected in any
ponies while IL-10 and IFN-a could be detected in indi-
vidual ponies of both infection groups on day 2 pi
(Additional file 2: Table S1). Overall levels for both
IL-10 and IFN-a were not significantly different from
controls because increases were only observed in indivi-
dual animals of each group. IFN-a was found in 5 out
of 7 animals in the Ab4 WT-infected group and 4 out
of 7 animals in the Ab4 ΔORF1/2-infected group, while
IL-10 was detectable at relatively low levels in 3 out of
7 animals in the Ab4 WT-infected group and 2 out of
7 animals in the Ab4 ΔORF1/2-infected group (Addi-
tional file 1: Table S1). IFN-a and IL-10 were not
detected on any other day in any animal.
Non-specific and EHV-1-specific lymphoproliferative
responses
Infection of ponies with either virus suppressed responses
in the two infection groups to PHA on day 7 pi when
compared to PBMCs of controls (Figure 5). This immuno-
suppressive effect disappeared by day 21 pi. Decreased
proliferative responses were observed only in T-lympho-
cytes for both infection groups when compared to controls
( p < 0.0001), while B-lymphocytes were not affected (data
not shown). Within the T-lymphocyte population, both
CD4+ and CD8+ lymphocytes were affected (Figure 5)
and the immunosuppression occurred at a PHA concen-
tration of both 1 μg/mL and 0.2 μg/mL (data not shown).
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Memory responses to EHV-1 that were above levels seen
in control animals were observed in T-lymphocytes of
both infection groups by day 96 pi, however the two infec-
tion groups were not significantly different (data not
shown).
Cytokine mRNA responses to in vitro re-stimulation with
EHV-1
Re-stimulation of PBMCs collected on days 74 and 96 pi
with WT Ab4 resulted in an increased IFN-g and Gran-
zyme B mRNA expression in both infection groups
Figure 3 EHV-1 serum neutralization titers (a) and kinetic ELISA IgG subclass anti-EHV-1 antibody responses (b-e). Controls (n = 5):
white circles, Ab4 WT infected (n = 7): grey triangles, Ab4 delta ORF1/2 infected (n = 7): black squares. Data are displayed as means + SEM.
Asterisks indicate statistically significant differences between infection groups, + indicates significant differences with the controls (p < 0.05).
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Figure 4 EHV-1 specific cytokine mRNA responses at days 1-7 pi. Relative quantities (RQ) represent x-fold increases over average levels
observed for the same cytokine on day -2 prior the experimental infections. Controls (n = 5): white bars, Ab4 WT infected (n = 7): grey bars,
Ab4 delta ORF1/2 infected (n = 7): black bars. Days 1-7 pi are represented by figure a-g respectively. Data are displayed as means + SEM.
A statistical difference from the control group is indicated by an * (p < 0.05) and between the two infection groups by an + (p < 0.05).
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when compared to uninfected controls, although these
differences did not reach significance (data not shown).
No differences were seen for Perforin mRNA expression
in PBMCs collected from the three experimental groups.
Stimulation with PHA resulted in increases in cytokine
mRNA expression for IFN-g, Perforin and Granzyme B
in all three groups when compared to media stimulation
only, but no differences were observed between experi-
mental groups (data not shown).
Discussion
This study describes how infection of ponies with EHV-
1 leads to viral modulation of equine immune responses
and identifies two new EHV-1 genes with function in
immunomodulation and disease attenuation. The
sequential characterization of cytokine responses during
the first seven days following infection with Ab4 WT
virus shows that increases in pro-inflammatory (IL-1,
IFN-a, TNF-a), T-helper 1 associated (IFN-g,) and regu-
latory cytokines (TGF-b and IL-10) coincide with the
biphasic increases in body temperature and the onset of
respiratory disease and viremia respectively. In the per-
iod between, cytokine responses decreased in Ab4 WT-
infected ponies, while decreases in IL-8 were attenuated
in Ab4 ΔORF1/2 virus infected ponies and Tbet
responses were increased compared to Ab4 WT-infected
ponies and controls.
Similar to what has been reported in murine studies of
EHV-1 infection [34], increases in cytokine/chemokine
responses with inflammatory, antiviral (IL-1, TNF-a,
(PBMCs) and IFN-a (nasal secretions)), and regulatory
function (TGF-b (PBMCs) and IL-10 (nasal secretions))
were seen in the first 48 h following infection. With
decreasing body temperatures, overall cytokine expression
returned to baseline levels and cytokine mRNA, associated
with cellular immune responses (IL-2 and Tbet) decreased
markedly in Ab4 WT virus infected ponies. Additionally, a
significant decrease of IL-8 mRNA was observed in AB4
WT infected ponies. Decreased levels of IL-8 mRNA
expression are consistent with previous in vitro and mur-
ine reports that have attributed this phenomenon to the
broad range of chemokine binding properties of the EHV-
1 glycoprotein G [6]. Parallel with the onset viremia,
increases in the mRNA expression of cytokines important
for the development of CTL-responses (IFN-g), as well as
increases in the expression of regulatory cytokines (IL-10
and TGF-b) were observed in PBMCs of infected ponies.
The latter is particularly interesting because we also found
a non-specific immunosuppression of T-cell responses in
both infection groups during this period. A study by
Charan et al. [35] found that post-EHV-1 infection autolo-
gous sera collected from horses on days 3 to 21 pi
contained increased levels of TGF-b and caused both non-
specific and EHV-1 specific suppression of T-cell
responses. This suppression was reversed by the addition
of an antibody to TGF-b [35]. Non-specific T-cell suppres-
sion in both the Charan et al. study and our present study
was temporary and disappeared by 21 pi. EHV-1 specific
proliferative T-cell responses and EHV-1-specific IFN-g
and Granzyme B responses increased only marginally in
infected ponies when compared with controls. Whether
immunosuppressive effects of the virus caused these
“weak” memory responses or whether our methodology
was not adequate to enumerate EHV-1 specific memory
responses remains to be determined. There are several
studies in the literature that were able to detect significant
CTL or IFN-g responses post EHV-1 infection, however,
responses were mostly significant in horses with prior
exposure or vaccination for EHV-1 [2,28,36-39].
Antibody responses in all three experimental groups
were measured by standard serum neutralizing test in
addition to a kinetic ELISA that determined IgG sub-
class responses as previously described [18]. Antibody
responses to EHV-1 infection in both infection groups
increased significantly by day 14 pi. The IgGa and IgGb
subclasses showed strong similarity to SN titer
responses, with the IgGb subclass response most closely
following the SN pattern consistent with prior observa-
tions [18,28]. Responses in the IgGc subclass, while sig-
nificant compared to uninfected controls, were of very
low amplitude and a role for this equine IgG subclass
has not been defined yet. For IgG(T), it was notable that
there was a pre-existing titer in all experimental groups
despite the fact that SN titers were negligible at this
time point, suggesting that IgG(T) responses do not
contribute substantially to SN titers or to protective
humoral immunity to EHV-1. As it has previously been
hypothesized that the IgGb/IgG(T) ratio may predict
protection from EHV-1 infection [17], IgGb/IgG(T)
Figure 5 Lymphoproliferative responses to in vitro stimulation
with PHA on day 7 post infection. Controls (n = 5): white bars,
Ab4 WT infected (n = 7): grey bars, Ab4 delta ORF1/2 infected (n = 7):
black bars. Data are displayed as means + SEM. A statistical difference
from the control group is indicated by * (p < 0.05).
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ratios were determined in our study, but were negligible,
most likely due to the low IgG(T) titers, and hence, may
not be of much value for assessing immune responses
(data not shown).
Deletion of the ORF1/2 genes from EHV-1 strain Ab4
attenuated EHV-1 disease and modulated IL-8 and Tbet
responses. Ab4 ΔORF1/2 infected ponies showed signifi-
cantly shortened primary fevers, and reduced nasal viral
shedding, despite the fact that both viruses show similar
in vitro growth kinetics. The significant reduction in
nasal viral shedding could be correlated with the increase
in IgGa production in the Ab4 ΔORF1/2 infected ponies.
However no significant increases in either SN titers or
IgGb, which are typically associated with increased clear-
ance of virus in nasal secretions, [40] were observed.
Alternatively, deletion of the ORF1/2 genes resulted in
increases of the chemokine IL-8 on days 3, 4 and 5 pi
when compared to infection with the Ab4 WT-virus.
This observation suggests that the ORF1/2 genes may
function in preventing chemotaxis, as has been described
for EHV-1 infection and so far been attributed to the gG
envelope protein only [6]. Deletion of the ORF1/2 genes
may thus have resulted in increased chemotaxis of pha-
gocytic cells and thus more rapid removal of infectious
virus, reflected by decreased viral shedding. Clearly, the
direct effects of these genes at the respiratory epithelium
need to be further investigated.
In addition, Ab4 ΔORF1/2 infected ponies exhibited
significantly increased Tbet mRNA expression in the
Ab4 WT-infected group. We speculate that the deletion
of the ORF1/2 genes may have allowed for the develop-
ment of TH 1 polarized immune responses, although no
other data were generated in the present study to sup-
port this. IFN-g responses to EHV-1 re-stimulation were
not found to be significantly different between infection
groups, suggesting that ORF1/2 deletion does not lead
to the induction of a stronger memory CTL response.
However, IFN-g mRNA expression does not correlate
perfectly with memory CTL responses [41] and standard
chromium release assays were not performed in this
study. Finally, while SN antibody responses and most
IgG isotype responses following infection were similar
for both infection groups, serum IgGa responses were
significantly increased in the Ab4 ΔORF1/2 group on
days 14 and 21 pi, which might again indicate that the
deletion of the ORF1/2 genes promoted a stronger
development of IgG isotype responses associated with
the development of TH-1 type immune responses [3].
In conclusion, we found that infection of ponies with
EHV-1 leads to modulation of equine immune responses,
which are closely correlated with disease pathogenesis. In
addition we have identified the ORF1/2 genes as two
additional genes which function in attenuating selected
clinical disease and nasal viral shedding and modulating
IL-8 and Tbet responses. It is clear that EHV-1, like
other a-herpesviruses has employed a plethora of
mechanisms to evade the host immune system, and
studying the in vivo function of responsible gene pro-
ducts is the first step for generation of a new class of
modified live vaccines for protection from EHV-1.
Additional material
Additional file 1: In vitro growth characteristics of the Ab4 WT and
ΔORF1/2 viruses. Titers were measured on RK-13 cells and represent
results of 3 repeats. Ab4 WT virusare represented as squares, Ab4 delta
ORF1/2 are represented as diamonds. Intracellular virus titers (a) and
extracellular viral titers (b) are depicted. Data are displayed as means ±
STDEV.
Additional file 2: Table S1. IFN-a, IL-10 and IL-4 levels in nasal
secretions collected on day 2 pi.
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